Back to top
more

Viatris (VTRS)

(Delayed Data from NSDQ)

$15.37 USD

15.37
22,642,136

-0.36 (-2.29%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $15.38 +0.01 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 43% (105 out of 247)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Viatris (VTRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates

by Zacks Equity Research

VTRS scores four regulatory wins in 2025, from FDA approval of a generic Sandostatin LAR to NDA and IND clearances across its pipeline.

Sundeep Ganoria headshot

ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?

by Sundeep Ganoria

ANIP's 53% YTD surge fuels strong 2025 financial performance, a raised outlook and powerful momentum in its rare disease portfolio.

Zacks Equity Research

Theravance's Q3 Earnings Surpass Estimates, Revenues Match

by Zacks Equity Research

TBPH delivers a third-quarter profit, beating estimates, and 19% revenue growth, fueled by rising collaboration income from Viatris related to Yupelri sales.

Zacks Equity Research

Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance

by Zacks Equity Research

Viatris tops Q3 earnings and revenue estimates, lifts 2025 outlook, and expands its Japan presence with Aculys Pharma deal.

Zacks Equity Research

Viatris (VTRS) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Viatris (VTRS) delivered earnings and revenue surprises of +6.35% and +3.09%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Countdown to Viatris (VTRS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Evaluate the expected performance of Viatris (VTRS) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Equity Research

Charles River Laboratories (CRL) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Charles River (CRL) delivered earnings and revenue surprises of +4.74% and +2.06%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Kanishka Das headshot

Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts?

by Kanishka Das

Let's look at five pharma and biotech companies, PFE, AMGN, AZN, VTRS and MRNA, which are scheduled to release their third-quarter 2025 results this week.